279 related articles for article (PubMed ID: 24903767)
21. Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy.
Martínez Leboráns L; Esteve Martínez A; Victoria Martínez AM; Alegre de Miquel V; Berrocal Jaime A
Dermatol Ther; 2016 Sep; 29(5):306-308. PubMed ID: 27357143
[No Abstract] [Full Text] [Related]
22. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
[TBL] [Abstract][Full Text] [Related]
23. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
24. Systematic review: colitis associated with anti-CTLA-4 therapy.
Gupta A; De Felice KM; Loftus EV; Khanna S
Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
[TBL] [Abstract][Full Text] [Related]
25. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
[TBL] [Abstract][Full Text] [Related]
26. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
Bronstein Y; Ng CS; Hwu P; Hwu WJ
AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma.
Toumeh A; Sakhi R; Shah S; Arudra SK; De Las Casas LE; Skeel RT
Am J Ther; 2016; 23(4):e1068-71. PubMed ID: 25933140
[TBL] [Abstract][Full Text] [Related]
28. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.
Wilgenhof S; Morlion V; Seghers AC; Du Four S; Vanderlinden E; Hanon S; Vandenbroucke F; Everaert H; Neyns B
Anticancer Res; 2012 Apr; 32(4):1355-9. PubMed ID: 22493370
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
Di Giacomo AM; Margolin K
Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Buchbinder EI; McDermott DF
Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
[TBL] [Abstract][Full Text] [Related]
31. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
32. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
33. Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.
Kopecký J; Trojanová P; Kubeček O; Kopecký O
Jpn J Clin Oncol; 2015 Apr; 45(4):381-4. PubMed ID: 25583422
[TBL] [Abstract][Full Text] [Related]
34. Ipilimumab in the treatment of melanoma.
Trinh VA; Hwu WJ
Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
[TBL] [Abstract][Full Text] [Related]
35. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
[TBL] [Abstract][Full Text] [Related]
36. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
37. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
[TBL] [Abstract][Full Text] [Related]
38. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N
Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275
[TBL] [Abstract][Full Text] [Related]
39. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
40. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]